A Study of PHN-010 in Patients With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT06457997

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT06457997. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

First-in-Human, Phase 1b Study of PHN-010, an Antibody Drug Conjugate, in Patients With Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-010, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.

Study identification

NCT ID: NCT06457997
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Pheon Therapeutics; Industry
Enrollment: 26 participants

Conditions and interventions

Conditions

Interventions

PHN-010 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 1, 2024 (Actual)
Primary completion: Sep 11, 2025 (Actual)
Completion: Sep 11, 2025 (Actual)
Last update posted: Jan 29, 2026

2024 – 2025

United States locations

U.S. sites: 8
U.S. states: 7
U.S. cities: 8

Facility	City	State	ZIP	Site status
AdventHealth	Orlando	Florida	32804	—
Dana Farber Cancer Institute	Boston	Massachusetts	02215	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
Sarah Cannon Research Institute	Nashville	Tennessee	37203	—
MD Anderson Cancer Center	Houston	Texas	77030	—
NEXT - San Antonio	San Antonio	Texas	78229	—
NEXT - Virginia	Fairfax	Virginia	22031	—
University of Washington/Fred Hutchinson Cancer Center	Seattle	Washington	98109	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06457997, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 29, 2026 · Synced Nov 14, 2026